Correlation Between Connect Biopharma and Nuvectis Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Connect Biopharma and Nuvectis Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Connect Biopharma and Nuvectis Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Connect Biopharma Holdings and Nuvectis Pharma, you can compare the effects of market volatilities on Connect Biopharma and Nuvectis Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Connect Biopharma with a short position of Nuvectis Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Connect Biopharma and Nuvectis Pharma.

Diversification Opportunities for Connect Biopharma and Nuvectis Pharma

-0.03
  Correlation Coefficient

Good diversification

The 3 months correlation between Connect and Nuvectis is -0.03. Overlapping area represents the amount of risk that can be diversified away by holding Connect Biopharma Holdings and Nuvectis Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nuvectis Pharma and Connect Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Connect Biopharma Holdings are associated (or correlated) with Nuvectis Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nuvectis Pharma has no effect on the direction of Connect Biopharma i.e., Connect Biopharma and Nuvectis Pharma go up and down completely randomly.

Pair Corralation between Connect Biopharma and Nuvectis Pharma

Given the investment horizon of 90 days Connect Biopharma Holdings is expected to under-perform the Nuvectis Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Connect Biopharma Holdings is 1.74 times less risky than Nuvectis Pharma. The stock trades about -0.04 of its potential returns per unit of risk. The Nuvectis Pharma is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  680.00  in Nuvectis Pharma on September 3, 2024 and sell it today you would lose (176.00) from holding Nuvectis Pharma or give up 25.88% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Connect Biopharma Holdings  vs.  Nuvectis Pharma

 Performance 
       Timeline  
Connect Biopharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Connect Biopharma Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.
Nuvectis Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Nuvectis Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Nuvectis Pharma is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Connect Biopharma and Nuvectis Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Connect Biopharma and Nuvectis Pharma

The main advantage of trading using opposite Connect Biopharma and Nuvectis Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Connect Biopharma position performs unexpectedly, Nuvectis Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nuvectis Pharma will offset losses from the drop in Nuvectis Pharma's long position.
The idea behind Connect Biopharma Holdings and Nuvectis Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Complementary Tools

Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk